Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Granulocyte Macrophage Colony Stimulating Factor Companies

ID: MRFR/Pharma/4951-HCR
100 Pages
Rahul Gotadki
Last Updated: February 16, 2025
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is a naturally occurring protein in the body that stimulates the production and function of white blood cells, including granulocytes and macrophages. GM-CSF is used therapeutically in medicine to boost the immune system, particularly in individuals undergoing certain medical treatments. Companies involved in GM-CSF development and manufacturing play a crucial role in providing therapeutic solutions.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Granulocyte Macrophage Colony Stimulating Factor Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.5%
2024 Market Size$ 0.24 Billion
2025 Market Size$ 0.26 Billion
2035 Market Size$ 0.49 Billion
Key Players
Amgen
Bristol-Myers Squibb
Novartis
Roche
Sanofi
Merck & Co.
Opportunities
  • Regulatory Support for Biologics
  • Rising Awareness of Immune Health
  • Increasing Prevalence of Chronic Diseases

Top Industry Leaders in the Granulocyte Macrophage Colony Stimulating Factor Market

Granulocyte-Macrophage Colony-Stimulating Factor Key Companies
ย 

Latest Granulocyte-Macrophage Colony-Stimulating Factor Companies Update

Chugai Pharmaceutical The leading manufacturer of filgrastim (Granulocyte) announced plans to expand their global production capacity due to increasing demand for the GM-CSF therapy.

Coherus BioSciences Received US FDA approval for Udencya, a biosimilar version of pegfilgrastim, offering a more affordable alternative for managing chemotherapy-induced neutropenia.

Kyowa Hakko Kirin Developed a long-acting GM-CSF variant (NKTR-102) in collaboration with Nektar Therapeutics, demonstrating promising efficacy in clinical trials for neutropenia prevention.

List of Granulocyte-Macrophage Colony-Stimulating Factor Key Companies in the Market

  • Xconomy Inc.
  • Partner Therapeutics (PTx)
  • Sanofi-Aventis U.S. LLC
  • Novartis AG
  • Thermo Fisher Scientific
  • Merck KGaA